The effect of Propofol versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer’s Disease: Results of a Randomized Trial

Manuscript Number: 

15-1190R2

Author(s): 
Ellen R. Bennett, Miles Berger, Mary Cooter, Allan Friedman, Michael L. James, Daniel T. Laskowitz, Joseph P. Mathew, David L. McDonagh, Jacob W. Nadler, Mark F. Newman, Vikram Ponnusamy, Wenjing Qi, Leslie M. Shaw, David S. Warner

Disclosures

Ellen R. Bennett

  • Nothing to Disclose

Miles Berger

  • Grants
    • Agency: 
      Minnetronix, Inc.
      Dates: 
      2014-2015

Mary Cooter

  • Nothing to Disclose

Allan Friedman

  • Nothing to Disclose

Michael L. James

  • Nothing to Disclose

Daniel T. Laskowitz

  • Consulting Fees:
    I have consulted for UCB Pharma, although not in the past year. I have consulted for Zenith Insurance. I have consulted for NeurOp, INc (unpaid) I have had no consulting related to this manuscript or the topic of this manuscript
    Equity:
    I own stock options in Astute, Inc; and equity in Cerenova, LLC; NeurOp
    Patents/Royalties
    I have a patent related to the the identification of a neuroprotective peptide. This is patented through Duke University, and is unrelated to the current manuscript.

Joseph P. Mathew

  • Nothing to Disclose

David L. McDonagh

  • Consulting Fees:
    Consultant for Lungpacer, Inc- unrelated to the research published here Consultant for Cephalogics Corp. LLC- unrelated to the research published here

Jacob W. Nadler

  • Nothing to Disclose

Mark F. Newman

  • Nothing to Disclose

Vikram Ponnusamy

  • Nothing to Disclose

Wenjing Qi

  • Nothing to Disclose

Leslie M. Shaw

  • Grants
    • Agency: 
      Roche
      Dates: 
      ongoing for studies involving standardization of AD and PD biomarkers

David S. Warner

  • Nothing to Disclose